Company Overview of Audeo Oncology, Inc.
Audeo Oncology, Inc., a biopharmaceutical company, primarily focuses on utilizing its Hyaluronic Acid Chemotransport technology (HyACT) to target cancer drugs to tumor cells to enhance drug activity. HyACT is a platform technology, which is designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. Its lead product candidate, HyACT-targeted irinotecan, is in a pivotal Phase III clinical trial for metastatic colorectal cancer (mCRC), as well as in Phase II clinical trial for the treatment of small cell lung cancer. The company also has two other Phase I/IIa clinical trial completed HyACT product candidates comprising HA-5-Fluorouracil and HA-Doxorubici...
100 Pine Street
San Francisco, CA 94111
Key Executives for Audeo Oncology, Inc.
Chief Financial Officer and Secretary
Chief Scientific Officer and Vice President of Oncology
Vice President of Business Development
Vice President of Discovery
Vice President of Intellectual Property & Technology Transfer
Compensation as of Fiscal Year 2014.
Audeo Oncology, Inc. Key Developments
Alchemia Limited and Audeo Oncology, Inc. Announce Management Changes
Jan 25 13
Alchemia Limited announced that Dr. Peter Smith, by mutual agreement with the board, will cease employment as the CEO and Managing Director with the Alchemia and Audeo Oncology. In the interim, Dr. Mel Bridges, the company's chairman will assume an executive chairman position, with the assurance to shareholders that the board will move quickly in the appointment of a replacement CEO. Dr. Bridges stressed that he will also keep shareholders and the market informed as to the revised plans for the Audeo Oncology assets. Given the failure of the US IPO for Audeo in late 2012, the board is in advanced planning on how best to maximize shareholder value for the oncology division heading into 2013.
Alchemia Oncology Pty Ltd. Announces New Board Appointments
Sep 30 12
Alchemia Limited announced the appointment of three independent non-executive directors to the board of its wholly-owned subsidiary, Alchemia Oncology Pty Ltd. (Audeo), in preparation for the upcoming demerger of Audeo. Leigh Bonney, Susan Kelley and David U'Prichard were appointed on September 28, 2012 to the board of directors of Audeo. Leigh Bonney has held senior positions in strategy and finance in the healthcare industry for much of her career including 15 years at Pfizer before retiring in 2011. Among the positions she held at Pfizer, she served as Chief Financial Officer of Pfizer Global Research and Development. Prior to Pfizer, Leigh worked for McKinsey and Company consulting to a number of industries including healthcare and pharmaceuticals. Leigh is currently the Chief Financial Officer of the Leona M. and Harry B. Helmsley Charitable Trust. Leigh has agreed to chair the Audit Committee of Audeo Oncology. Susan Kelley has held fellowships at the Dana-Farber Cancer Institute, Harvard Medical School and Yale School of Medicine. Susan has recently held senior positions in the pharmaceutical industry including Vice President Global Strategic Drug Development, Oncology and Metabolics with Bayer-Schering Pharmaceuticals and Therapeutic Area Head - Oncology with Bayer Pharmaceuticals. Susan has agreed to Chair the Nominations and Corporate Governance Committee of Audeo Oncology. David U'Prichard has had an extensive career in the management of drug discovery and development and currently advises life sciences companies as President of Druid Consulting LLC. Previously, David was CEO of 3-Dimensional Pharmaceuticals and held the positions of President and Chairman of Research and Development for SmithKline Beecham Pharmaceuticals and Executive Vice President and international Research Director and Member of the Board and Management of Zeneca Pharmaceuticals. David has agreed to Chair the Compensation Committee of Audeo Oncology.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries